The Needle-Free Future

Vaxxas' HD-MAP technology uses a patch with thousands of vaccine-coated microprojections that is applied to the skin for a few seconds to efficiently deliver vaccine to the abundant immune cells immediately below the skin surface.

Empowered To Do More

Vaxxas' approach shifts the value paradigm of vaccines. Vaxxas' HD-MAP platform has been:

  • Productized for commercial use
  • Validated in human clinical studies
  • Designed for manufacture at scale

The People And Partners Behind Vaxxas

Our Team

We have assembled a passionate and experienced team committed to rethinking what’s possible with vaccines.

Partners

We partner with world renowned organizations to maximize the impact of our technology for people globally.

Explore what's possible for you
with Careers at Vaxxas

Vaxxas In The News

June 02, 2021

Preclinical Studies From Vaxxas and Collaborators Reveal Potential of Vaxxas' Novel High-Density Microarray Patch (HD-MAP) to Effectively Deliver SARS-CoV-2 Spike Vaccine